Literature DB >> 2312682

Canine ehrlichiosis in Connecticut.

L A Magnarelli1, H J Litwin, C J Holland, J F Anderson, M Ristic.   

Abstract

The first case of canine ehrlichiosis in Connecticut is reported. A female Brittany spaniel from Milford presented with lethargy, anorexia, fever, petechiae, splenomegaly, thrombocytopenia, anemia, elevated serum alkaline phosphatase, lymphopenia, and hypoalbuminemia. Serologic analysis revealed antibodies to Ehrlichia canis (titer, 1:2,560). This documents a more northern geographic distribution in the United States for this infectious agent than had previously been suspected.

Entities:  

Mesh：

Year:  1990        PMID： 2312682      PMCID： PMC269610          DOI： 10.1128/jcm.28.2.366-367.1990

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  13 in total

1.  Ehrlichiosis: a cause of bone marrow hypoplasia in humans.

Authors:  C J Pearce; M E Conrad; P E Nolan; D B Fishbein; J E Dawson
Journal:  Am J Hematol       Date:  1988-05       Impact factor: 10.047

2.  Human infection with Ehrlichia canis, a leukocytic rickettsia.

Authors:  K Maeda; N Markowitz; R C Hawley; M Ristic; D Cox; J E McDade
Journal:  N Engl J Med       Date:  1987-04-02       Impact factor: 91.245

3.  An outbreak of ehrlichiosis in members of an Army Reserve unit exposed to ticks.

Authors:  L R Petersen; L A Sawyer; D B Fishbein; P W Kelley; R J Thomas; L A Magnarelli; M Redus; J E Dawson
Journal:  J Infect Dis       Date:  1989-03       Impact factor: 5.226

4.  Distribution of Ehrlichia canis among military working dogs in the world and selected civilian dogs in the United States.

Authors:  T J Keefe; C J Holland; P E Salyer; M Ristic
Journal:  J Am Vet Med Assoc       Date:  1982-08-01       Impact factor: 1.936

5.  The brown dog tick Rhipicephalus sanguineus and the dog as experimental hosts of Ehrlichia canis.

Authors:  G E Lewis; M Ristic; R D Smith; T Lincoln; E H Stephenson
Journal:  Am J Vet Res       Date:  1977-12       Impact factor: 1.156

6.  Prophylactic and therapeutic use of tetracycline during an epizootic of ehrlichiosis among military dogs.

Authors:  D E Davidson; G S Dill; M Tingpalapong; S Premabutra; P L Nguen; E H Stephenson; M Ristic
Journal:  J Am Vet Med Assoc       Date:  1978-03-15       Impact factor: 1.936

7.  Serological diagnosis of tropical canine pancytopenia by indirect immunofluorescence.

Authors:  M Ristic; D L Huxsoll; R M Weisiger; P K Hildebrandt; M B Nyindo
Journal:  Infect Immun       Date:  1972-09       Impact factor: 3.441

8.  Unexplained febrile illnesses after exposure to ticks. Infection with an Ehrlichia?

Authors:  D B Fishbein; L A Sawyer; C J Holland; E B Hayes; W Okoroanyanwu; D Williams; K Sikes; M Ristic; J E McDade
Journal:  JAMA       Date:  1987-06-12       Impact factor: 56.272

9.  A comparison of the efficacy of imidocarb dipropionate and tetracycline hydrochloride in the treatment of canine ehrlichiosis.

Authors:  J E Price; T T Dolan
Journal:  Vet Rec       Date:  1980-09-20       Impact factor: 2.695

10.  Tropical canine pancytopenia: Clinical, hematologic, and serologic response of dogs to Ehrlichia canis infection, tetracycline therapy, and challenge inoculation.

Authors:  W C Buhles; D L Huxsoll; M Ristic
Journal:  J Infect Dis       Date:  1974-10       Impact factor: 5.226
View more
  3 in total

1.  Rickettsiae and Borrelia burgdorferi in ixodid ticks.

Authors:  L A Magnarelli; T G Andreadis; K C Stafford; C J Holland
Journal:  J Clin Microbiol       Date:  1991-12       Impact factor: 5.948

2.  Serologic evidence of canine and equine ehrlichiosis in northeastern United States.

Authors:  L A Magnarelli; J F Anderson
Journal:  J Clin Microbiol       Date:  1993-11       Impact factor: 5.948

Review 3.  Host surveys, ixodid tick biology and transmission scenarios as related to the tick-borne pathogen, Ehrlichia canis.

Authors:  R W Stich; John J Schaefer; William G Bremer; Glen R Needham; Sathaporn Jittapalapong
Journal:  Vet Parasitol       Date:  2008-09-12       Impact factor: 2.738
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.